GSK Inks $750M Deal to Add Experimental Blood Cancer Therapy

GSK has agreed to acquire global rights to Chimagen Biosciences' investigational trispecific T-cell engager (TCE) for up to $750 million. The candidate targets two tumor-associated antigens simultaneously and is designed to improve efficacy and tolerability in multiple myeloma treatment, with Phase I studies expected to begin in 2027. This acquisition expands GSK's multiple myeloma portfolio and strengthens its focus on multi-specific T-cell therapies.